title: Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice.
abstract: Colorectal cancer remains one of the most common types of cancer and leading causes of cancer death worldwide. Although we have made steady progress in chemotherapy and targeted therapy, evidence suggests that the majority of patients undergoing drug therapy experience severe, debilitating, and even lethal adverse drug events which considerably outweigh the benefits. The identification of suitable biomarkers will allow clinicians to deliver the most appropriate drugs to specific patients and spare them ineffective and expensive treatments. Prognostic and predictive biomarkers have been the subjects of many published papers, but few have been widely incorporated into clinical practice. Here, we want to review recent biomarker data related to colorectal cancer, which may have been ready for clinical use.
authors.affiliation: Cancer Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
authors.forename: Wei-qin
authors.initials: WQ
authors.lastname: Jiang
authors.forename: Fang-fang
authors.initials: FF
authors.lastname: Fu
authors.forename: Yang-xia
authors.initials: YX
authors.lastname: Li
authors.forename: Wei-bin
authors.initials: WB
authors.lastname: Wang
authors.forename: Hao-hao
authors.initials: HH
authors.lastname: Wang
authors.forename: Hai-ping
authors.initials: HP
authors.lastname: Jiang
authors.forename: Li-song
authors.initials: LS
authors.lastname: Teng
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000235:genetics*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000378:metabolism; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005472:Fluorouracil / Q000009:adverse effects / Q000378:metabolism; D006801:Humans; D000077146:Irinotecan; D058990:Molecular Targeted Therapy; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000378:metabolism; D000077150:Oxaliplatin; D011237:Predictive Value of Tests; D011379:Prognosis; D059467:Transcriptome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009944:Organoplatinum Compounds; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000077150:Oxaliplatin; D000077146:Irinotecan; D066246:ErbB Receptors; D005472:Fluorouracil; D002166:Camptothecin